Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy

Mohanraj Rajesh, Partha Mukhopadhyay, Sándor Bátkai, Bani Mukhopadhyay, Vivek Patel, György Haskó, Csaba Szabo, Jon G. Mabley, Lucas Liaudet, Pál Pacher

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

In this study, we investigated the effect of the xanthine oxidase (XO) inhibitor, allopurinol (ALP), on cardiac dysfunction, oxidative-nitrosative stress, apoptosis, poly(ADP-ribose) polymerase (PARP) activity and fibrosis associated with diabetic cardiomyopathy in mice. Diabetes was induced in C57/BL6 mice by injection of streptozotocin. Control and diabetic animals were treated with ALP or placebo. Left ventricular systolic and diastolic functions were measured by pressure-volume system 10 weeks after established diabetes. Myocardial XO, p22phox, p40phox, p47phox, gp91phox, iNOS, eNOS mRNA and/or protein levels, ROS and nitrotyrosine (NT) formation, caspase3/7 and PARP activity, chromatin fragmentation and various markers of fibrosis (collagen-1, TGF-β, CTGF, fibronectin) were measured using molecular biology and biochemistry methods or immunohistochemistry. Diabetes was characterized by increased myocardial, liver and serum XO activity (but not expression), increased myocardial ROS generation, p22phox, p40phox, p47phox, p91phox mRNA expression, iNOS (but not eNOS) expression, NT generation, caspase 3/7 and PARP activity/expression, chromatin fragmentation and fibrosis (enhanced accumulation of collagen, TGF-β, CTGF and fibronectin), and declined systolic and diastolic myocardial performance. ALP attenuated the diabetes-induced increased myocardial, liver and serum XO activity, myocardial ROS, NT generation, iNOS expression, apoptosis, PARP activity and fibrosis, which were accompanied by improved systolic (measured by the evaluation of both load-dependent and independent indices of myocardial contractility) and diastolic performance of the hearts of treated diabetic animals. Thus, XO inhibition with ALP improves type 1 diabetes-induced cardiac dysfunction by decreasing oxidative/nitrosative stress and fibrosis, which may have important clinical implications for the treatment and prevention of diabetic cardiomyopathy and vascular dysfunction.

Original languageEnglish (US)
Pages (from-to)2330-2341
Number of pages12
JournalJournal of Cellular and Molecular Medicine
Volume13
Issue number8 B
DOIs
StatePublished - Aug 2009

Fingerprint

Diabetic Cardiomyopathies
Allopurinol
Xanthine Oxidase
Poly(ADP-ribose) Polymerases
Fibrosis
Fibronectins
Chromatin
Oxidative Stress
Collagen
Apoptosis
Caspase 7
Messenger RNA
Liver
Streptozocin
Serum
Type 1 Diabetes Mellitus
Caspase 3
Biochemistry
Blood Vessels
Molecular Biology

Keywords

  • Diabetic cardiomyopathy
  • Fibrosis
  • INOS
  • Oxidative stress
  • Peroxynitrite

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

Rajesh, M., Mukhopadhyay, P., Bátkai, S., Mukhopadhyay, B., Patel, V., Haskó, G., ... Pacher, P. (2009). Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. Journal of Cellular and Molecular Medicine, 13(8 B), 2330-2341. https://doi.org/10.1111/j.1582-4934.2008.00564.x

Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. / Rajesh, Mohanraj; Mukhopadhyay, Partha; Bátkai, Sándor; Mukhopadhyay, Bani; Patel, Vivek; Haskó, György; Szabo, Csaba; Mabley, Jon G.; Liaudet, Lucas; Pacher, Pál.

In: Journal of Cellular and Molecular Medicine, Vol. 13, No. 8 B, 08.2009, p. 2330-2341.

Research output: Contribution to journalArticle

Rajesh, M, Mukhopadhyay, P, Bátkai, S, Mukhopadhyay, B, Patel, V, Haskó, G, Szabo, C, Mabley, JG, Liaudet, L & Pacher, P 2009, 'Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy', Journal of Cellular and Molecular Medicine, vol. 13, no. 8 B, pp. 2330-2341. https://doi.org/10.1111/j.1582-4934.2008.00564.x
Rajesh, Mohanraj ; Mukhopadhyay, Partha ; Bátkai, Sándor ; Mukhopadhyay, Bani ; Patel, Vivek ; Haskó, György ; Szabo, Csaba ; Mabley, Jon G. ; Liaudet, Lucas ; Pacher, Pál. / Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. In: Journal of Cellular and Molecular Medicine. 2009 ; Vol. 13, No. 8 B. pp. 2330-2341.
@article{7932e4618032417fafbece3076827f92,
title = "Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy",
abstract = "In this study, we investigated the effect of the xanthine oxidase (XO) inhibitor, allopurinol (ALP), on cardiac dysfunction, oxidative-nitrosative stress, apoptosis, poly(ADP-ribose) polymerase (PARP) activity and fibrosis associated with diabetic cardiomyopathy in mice. Diabetes was induced in C57/BL6 mice by injection of streptozotocin. Control and diabetic animals were treated with ALP or placebo. Left ventricular systolic and diastolic functions were measured by pressure-volume system 10 weeks after established diabetes. Myocardial XO, p22phox, p40phox, p47phox, gp91phox, iNOS, eNOS mRNA and/or protein levels, ROS and nitrotyrosine (NT) formation, caspase3/7 and PARP activity, chromatin fragmentation and various markers of fibrosis (collagen-1, TGF-β, CTGF, fibronectin) were measured using molecular biology and biochemistry methods or immunohistochemistry. Diabetes was characterized by increased myocardial, liver and serum XO activity (but not expression), increased myocardial ROS generation, p22phox, p40phox, p47phox, p91phox mRNA expression, iNOS (but not eNOS) expression, NT generation, caspase 3/7 and PARP activity/expression, chromatin fragmentation and fibrosis (enhanced accumulation of collagen, TGF-β, CTGF and fibronectin), and declined systolic and diastolic myocardial performance. ALP attenuated the diabetes-induced increased myocardial, liver and serum XO activity, myocardial ROS, NT generation, iNOS expression, apoptosis, PARP activity and fibrosis, which were accompanied by improved systolic (measured by the evaluation of both load-dependent and independent indices of myocardial contractility) and diastolic performance of the hearts of treated diabetic animals. Thus, XO inhibition with ALP improves type 1 diabetes-induced cardiac dysfunction by decreasing oxidative/nitrosative stress and fibrosis, which may have important clinical implications for the treatment and prevention of diabetic cardiomyopathy and vascular dysfunction.",
keywords = "Diabetic cardiomyopathy, Fibrosis, INOS, Oxidative stress, Peroxynitrite",
author = "Mohanraj Rajesh and Partha Mukhopadhyay and S{\'a}ndor B{\'a}tkai and Bani Mukhopadhyay and Vivek Patel and Gy{\"o}rgy Hask{\'o} and Csaba Szabo and Mabley, {Jon G.} and Lucas Liaudet and P{\'a}l Pacher",
year = "2009",
month = "8",
doi = "10.1111/j.1582-4934.2008.00564.x",
language = "English (US)",
volume = "13",
pages = "2330--2341",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "8 B",

}

TY - JOUR

T1 - Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy

AU - Rajesh, Mohanraj

AU - Mukhopadhyay, Partha

AU - Bátkai, Sándor

AU - Mukhopadhyay, Bani

AU - Patel, Vivek

AU - Haskó, György

AU - Szabo, Csaba

AU - Mabley, Jon G.

AU - Liaudet, Lucas

AU - Pacher, Pál

PY - 2009/8

Y1 - 2009/8

N2 - In this study, we investigated the effect of the xanthine oxidase (XO) inhibitor, allopurinol (ALP), on cardiac dysfunction, oxidative-nitrosative stress, apoptosis, poly(ADP-ribose) polymerase (PARP) activity and fibrosis associated with diabetic cardiomyopathy in mice. Diabetes was induced in C57/BL6 mice by injection of streptozotocin. Control and diabetic animals were treated with ALP or placebo. Left ventricular systolic and diastolic functions were measured by pressure-volume system 10 weeks after established diabetes. Myocardial XO, p22phox, p40phox, p47phox, gp91phox, iNOS, eNOS mRNA and/or protein levels, ROS and nitrotyrosine (NT) formation, caspase3/7 and PARP activity, chromatin fragmentation and various markers of fibrosis (collagen-1, TGF-β, CTGF, fibronectin) were measured using molecular biology and biochemistry methods or immunohistochemistry. Diabetes was characterized by increased myocardial, liver and serum XO activity (but not expression), increased myocardial ROS generation, p22phox, p40phox, p47phox, p91phox mRNA expression, iNOS (but not eNOS) expression, NT generation, caspase 3/7 and PARP activity/expression, chromatin fragmentation and fibrosis (enhanced accumulation of collagen, TGF-β, CTGF and fibronectin), and declined systolic and diastolic myocardial performance. ALP attenuated the diabetes-induced increased myocardial, liver and serum XO activity, myocardial ROS, NT generation, iNOS expression, apoptosis, PARP activity and fibrosis, which were accompanied by improved systolic (measured by the evaluation of both load-dependent and independent indices of myocardial contractility) and diastolic performance of the hearts of treated diabetic animals. Thus, XO inhibition with ALP improves type 1 diabetes-induced cardiac dysfunction by decreasing oxidative/nitrosative stress and fibrosis, which may have important clinical implications for the treatment and prevention of diabetic cardiomyopathy and vascular dysfunction.

AB - In this study, we investigated the effect of the xanthine oxidase (XO) inhibitor, allopurinol (ALP), on cardiac dysfunction, oxidative-nitrosative stress, apoptosis, poly(ADP-ribose) polymerase (PARP) activity and fibrosis associated with diabetic cardiomyopathy in mice. Diabetes was induced in C57/BL6 mice by injection of streptozotocin. Control and diabetic animals were treated with ALP or placebo. Left ventricular systolic and diastolic functions were measured by pressure-volume system 10 weeks after established diabetes. Myocardial XO, p22phox, p40phox, p47phox, gp91phox, iNOS, eNOS mRNA and/or protein levels, ROS and nitrotyrosine (NT) formation, caspase3/7 and PARP activity, chromatin fragmentation and various markers of fibrosis (collagen-1, TGF-β, CTGF, fibronectin) were measured using molecular biology and biochemistry methods or immunohistochemistry. Diabetes was characterized by increased myocardial, liver and serum XO activity (but not expression), increased myocardial ROS generation, p22phox, p40phox, p47phox, p91phox mRNA expression, iNOS (but not eNOS) expression, NT generation, caspase 3/7 and PARP activity/expression, chromatin fragmentation and fibrosis (enhanced accumulation of collagen, TGF-β, CTGF and fibronectin), and declined systolic and diastolic myocardial performance. ALP attenuated the diabetes-induced increased myocardial, liver and serum XO activity, myocardial ROS, NT generation, iNOS expression, apoptosis, PARP activity and fibrosis, which were accompanied by improved systolic (measured by the evaluation of both load-dependent and independent indices of myocardial contractility) and diastolic performance of the hearts of treated diabetic animals. Thus, XO inhibition with ALP improves type 1 diabetes-induced cardiac dysfunction by decreasing oxidative/nitrosative stress and fibrosis, which may have important clinical implications for the treatment and prevention of diabetic cardiomyopathy and vascular dysfunction.

KW - Diabetic cardiomyopathy

KW - Fibrosis

KW - INOS

KW - Oxidative stress

KW - Peroxynitrite

UR - http://www.scopus.com/inward/record.url?scp=72949089507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72949089507&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2008.00564.x

DO - 10.1111/j.1582-4934.2008.00564.x

M3 - Article

C2 - 19175688

AN - SCOPUS:72949089507

VL - 13

SP - 2330

EP - 2341

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 8 B

ER -